Emcure Pharmaceuticals Limited (NSE:EMCURE)

Emcure Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	1,475	1,555	1,690	2,423	1,628
Short-Term Investments	-	760.43	2,997	2,045	-
Cash & Short-Term Investments	1,475	2,316	4,687	4,468	1,628
Cash Growth	-36.30%	-50.59%	4.88%	174.38%	-66.33%
Accounts Receivable	25,627	20,022	18,588	16,483	13,085
Other Receivables	687.38	531.97	731.86	703.62	461.91
Receivables	26,314	20,554	19,320	17,187	13,547
Inventory	23,979	19,885	15,891	14,593	15,593
Prepaid Expenses	-	326.05	304.41	198.6	330.53
Other Current Assets	4,353	2,477	2,397	1,912	3,142
Total Current Assets	56,121	45,559	42,599	38,359	34,241
Property, Plant & Equipment	24,908	24,271	23,972	22,148	19,855
Long-Term Investments	197.03	221.26	199.85	557.78	440.37
Goodwill	4,143	3,678	3,787	2,177	2,174
Other Intangible Assets	6,868	5,792	5,078	1,258	1,614
Long-Term Deferred Tax Assets	1,394	1,110	967.96	991.26	1,161
Other Long-Term Assets	2,494	1,696	1,458	1,234	1,150
Total Assets	96,125	82,327	78,062	66,725	60,635

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	18,078	14,796	13,094	10,861	11,252
Accrued Expenses	722.64	2,571	2,418	2,782	2,457
Short-Term Debt	-	4,747	9,486	11,333	10,866
Current Portion of Long-Term Debt	9,519	670.79	3,721	3,175	2,797
Current Portion of Leases	548.78	337.28	319.19	241.9	222.96
Current Income Taxes Payable	1,430	1,123	534.45	487.75	621.52
Current Unearned Revenue	-	-	-	178.65	271.39
Other Current Liabilities	8,825	2,438	2,532	1,132	1,160
Total Current Liabilities	39,122	26,683	32,105	30,192	29,648
Long-Term Debt	2,522	1,899	7,666	7,441	7,173
Long-Term Leases	2,623	2,573	2,157	1,152	1,113
Long-Term Unearned Revenue	73.04	300.25	403.08	307.32	393.7
Long-Term Deferred Tax Liabilities	980	1,200	1,374	388.95	426.14
Other Long-Term Liabilities	1,038	3,256	3,139	747.37	739.54
Total Liabilities	46,358	35,912	46,844	40,229	39,493

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	1,896	1,895	1,812	1,809	1,809
Additional Paid-In Capital	-	7,853	98.84	-	-
Retained Earnings	-	33,767	26,980	22,789	17,751
Comprehensive Income & Other	47,604	947.24	632.25	413.54	315.91
Total Common Equity	49,500	44,462	29,523	25,011	19,875
Minority Interest	266.41	1,954	1,695	1,485	1,266
Shareholders' Equity	49,767	46,416	31,218	26,497	21,141
Total Liabilities & Equity	96,125	82,327	78,062	66,725	60,635

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	15,212	10,227	23,350	23,343	22,172
Net Cash (Debt)	-13,737	-7,912	-18,663	-18,875	-20,544
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-72.48	-42.30	-103.18	-104.37	-113.59
Filing Date Shares Outstanding	189.57	189.48	181.15	180.85	180.85
Total Common Shares Outstanding	189.57	189.48	181.15	180.85	180.85
Working Capital	16,999	18,876	10,494	8,167	4,593
Book Value Per Share	261.12	234.65	162.97	138.30	109.90
Tangible Book Value	38,489	34,992	20,658	21,576	16,088
Tangible Book Value Per Share	203.04	184.67	114.04	119.30	88.96
Land	-	529.12	526.46	533.22	522.55
Buildings	-	6,199	5,953	5,478	4,901
Machinery	-	27,491	25,498	20,713	18,271
Construction In Progress	-	1,241	1,323	4,035	3,098
Leasehold Improvements	-	656.11	583.3	368.83	324.63

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 1, 2026

Data Sources Report a data error